Sector • Consumer Non Cyclical Industry • Legal Cannabis |
Industry • Legal Cannabis |
Sector • Consumer Non Cyclical |
News about Mediwound Ltd
Evaluating Innovations in Wound Care MediWounds Phase II Study on EscharEx vs. Collagenase for Venous Leg Ulcers
Oct 10 2024
In a significant advance for the field of wound management, MediWound Ltd has announced the commencement of a Phase II head-to-head study assessing th...
In November 2023, MediWound Ltd announced the findings from the Phase II ChronEx study concerning EscharEx,...
Jul 29 2024
*The Evolution of Wound Care: MediWound?s EscharEx Study Results and Their Implications for Venous Leg Ulcer Management*In November 2023, MediWound Lt...
MediWound Secures $16.25 Million in Funding to Advance Revolutionary Treatment for Diabetic Foot Ulcers
Jul 16 2024
...
MediWound Secures $15 Million Investment from Mlnlycke Health Care, But Quick Ratio Rankings Decline in Q4 2023
Jul 15 2024
Mlnlycke Health Care, a global leader in innovative wound care solutions, has made a significant investment of $15 million in a private placement...
MediWound Ltd Outperforms Market Despite Recent Acquisition Reports
Jul 11 2024
In the past week, shares of Mediwound Ltd have shown a slight decline compared to the overall market performance. However, when looking at the bigger ...
Promising EscharEx Phase II Data Amidst Revenue Struggle: A Mediwound Analysis
Apr 25 2024
In-depth findings generated from the Phase II Studies of EscharEx, a product of MediWound, were recently revealed at three major global wound care con...
Legal Cannabis Industry Holds Steady Revenue in Fourth Quarter of 2023 Amidst Changing Market Trends
Mar 22 2024
Mediwound Ltd, a leading innovator in burn and wound care treatments, has experienced a decline of 10.77% in its shares during March 2024, which bring...
Revolutionizing Burn Treatment: FDA Acceptance Marks a New Dawn for Pediatric Burn Patients with NexoBrid
Jan 09 2024
MediWound Ltd, an innovator in burn and wound care treatments, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted fo...
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army
Dec 28 2023
MediWound Awarded $6.7 Million to Advance NexoBrid as a Non-Surgical Field Care Solution; R&D Budget Increased to $14.4 MillionMediWound, a lead...
Breaking New Ground in Wound Care: MediWound*s EscharEx Exceeds Expectations and Elevates Wound Treatment Standards
Dec 21 2023
In a recent peer-reviewed publication, MediWound Ltd, a leading biotechnology company specializing in innovative wound healing solutions, announced th...